Akoya Biosciences Stock (NASDAQ:AKYA)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$2.16

52W Range

$1.88 - $6.31

50D Avg

$2.90

200D Avg

$3.31

Market Cap

$107.06M

Avg Vol (3M)

$151.52K

Beta

1.35

Div Yield

-

AKYA Company Profile


Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Show More

Industry

Medical - Instruments & Supplies

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

330

IPO Date

Apr 16, 2021

Website

AKYA Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Service And Other$18.93M--
Product$67.41M$57.65M$44.48M
Service and other$29.22M$17.21M$10.44M
Consumables$24.13M$18.38M$14.30M
Instruments$42.09M$38.63M$28.69M
Standalone software products$1.18M$636.00K$1.49M

Fiscal year ends in Dec 23 | Currency in USD

AKYA Financial Summary


Dec 23Dec 22Dec 21
Revenue$96.63M$74.86M$54.92M
Operating Income$-57.67M$-66.21M$-37.23M
Net Income$-63.32M$-70.64M$-42.94M
EBITDA$-64.06M$-59.33M$-32.91M
Basic EPS-$-1.87$-1.60
Diluted EPS-$-1.87$-1.60

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 14, 24 | 9:43 PM
Q2 24Aug 05, 24 | 10:19 PM
Q1 24May 17, 24 | 8:36 PM

Peer Comparison


TickerCompany
COOThe Cooper Companies, Inc.
ATRCAtriCure, Inc.
ATRIAtrion Corporation
ANGOAngioDynamics, Inc.
LMATLeMaitre Vascular, Inc.
HAEHaemonetics Corporation
ICUIICU Medical, Inc.
ATRAptarGroup, Inc.
PDEXPro-Dex, Inc.
UTMDUtah Medical Products, Inc.